286 related articles for article (PubMed ID: 30562567)
1. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.
Casseres RG; Kahn JS; Her MJ; Rosmarin D
J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567
[No Abstract] [Full Text] [Related]
2. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
Vekic DA; Frew JW
Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
[No Abstract] [Full Text] [Related]
3. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases.
Houriet C; Seyed Jafari SM; Thomi R; Schlapbach C; Borradori L; Yawalkar N; Hunger RE
JAMA Dermatol; 2017 Nov; 153(11):1195-1197. PubMed ID: 28854317
[No Abstract] [Full Text] [Related]
4. Guselkumab in the treatment of severe hidradenitis suppurativa.
Kovacs M; Podda M
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e140-e141. PubMed ID: 30480844
[No Abstract] [Full Text] [Related]
5. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
Ghias MH; Johnston AD; Kutner AJ; Micheletti RG; Hosgood HD; Cohen SR
J Am Acad Dermatol; 2020 May; 82(5):1094-1101. PubMed ID: 31589948
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
[No Abstract] [Full Text] [Related]
7. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
Moul DK; Korman NJ
Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
[No Abstract] [Full Text] [Related]
8. Infliximab for the treatment of hidradenitis suppurativa.
Fernández-Vozmediano JM; Armario-Hita JC
Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
[TBL] [Abstract][Full Text] [Related]
9. Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
Tekin B; Salman A; Ergun T
Indian J Dermatol Venereol Leprol; 2017; 83(5):615-617. PubMed ID: 28731016
[No Abstract] [Full Text] [Related]
10. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
[No Abstract] [Full Text] [Related]
11. Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
Hotz C; Sbidian E; Ingen-Housz-Oro S; Chosidow O; Wolkenstein P
Acta Derm Venereol; 2019 Nov; 99(12):1170-1171. PubMed ID: 31314122
[No Abstract] [Full Text] [Related]
12. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
13. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
Alecsandru D; Padilla B; Izquierdo JA; Fernández-Cruz E; Sánchez-Ramón S
Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
[No Abstract] [Full Text] [Related]
14. Moderate to severe hidradenitis suppurativa treated with biological therapies.
Chinniah N; Cains GD
Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of hidradenitis suppurativa.
Lebwohl B; Sapadin AN
J Am Acad Dermatol; 2003 Nov; 49(5 Suppl):S275-6. PubMed ID: 14576652
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.
Sotiriou E; Apalla Z; Vakirlis E; Ioannides D
Eur J Dermatol; 2009; 19(2):180-1. PubMed ID: 19153066
[No Abstract] [Full Text] [Related]
17. Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa.
Braunberger TL; Lowes MA; Hamzavi IH
Int J Dermatol; 2019 Sep; 58(9):1090-1091. PubMed ID: 30094834
[No Abstract] [Full Text] [Related]
18. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.
Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Arias-Santiago S; Molina-Leyva A
Dermatol Ther; 2020 May; 33(3):e13456. PubMed ID: 32319172
[No Abstract] [Full Text] [Related]
19. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
Kanni T; Argyropoulou M; Spyridopoulos T; Pistiki A; Stecher M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
J Invest Dermatol; 2018 Apr; 138(4):795-801. PubMed ID: 29129600
[TBL] [Abstract][Full Text] [Related]
20. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
